VAS
LXRX icon

Vestmark Advisory Solutions’s Lexicon Pharmaceuticals LXRX Stock Holding History

Vestmark Advisory Solutions’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-42,418
Closed -$249K – 792
2021
Q1 		$249K Buy
+42,418
New +$294K 0.02% 652

Other funds holding LXRX

AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
PA
Pinnacle Associates New York $9.16B AUM 63.5% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vestmark Advisory Solutions's LXRX Position: Q2 2021 in Review

Vestmark Advisory Solutions sold out of Lexicon Pharmaceuticals (LXRX) in Q2 2021, closing a stake of 42,418 shares — an estimated $249K sold.

Vestmark Advisory Solutions first reported a position in LXRX in Q1 2021 and held it in 1 quarter. The position peaked at $249K in Q1 2021. 107 funds tracked by Wall St. Rank hold LXRX as of Q2 2021.

  • Vestmark Advisory Solutions reported no remaining Lexicon Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
  • Vestmark Advisory Solutions sold 42,418 Lexicon Pharmaceuticals shares in Q2 2021, an estimated $249K.
  • Vestmark Advisory Solutions first reported a position in Lexicon Pharmaceuticals in Q1 2021 and held it in 1 quarter.
  • Vestmark Advisory Solutions's Lexicon Pharmaceuticals position peaked at $249K in Q1 2021.
  • 107 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q2 2021.

Based on Vestmark Advisory Solutions's 13F filing for Q2 2021, filed 9 Aug 2021.